Levetiracetam-Rex

Quick links

Choose a section

Quick links to important sections

Advertisements

Levetiracetam-Rex

Advertisements
Advertisements

Method of action: Anticonvulsant, Antiepileptic

Advertisements

Overview of Levetiracetam-Rex

Quick Facts

Property Description
Active ingredient Levetiracetam (LEV)
Form Tablet (IR/ER), Oral Solution, Concentrate for Infusion
Pharmacological class Antiepileptic Drug (AED), Second-Generation
Common use Control of seizures related to epilepsy
Origin Synthetic (Pyrrolidone class)

What Type of Medicine is Levetiracetam-Rex?

Levetiracetam-Rex is a pharmaceutical product defined by its active ingredient, Levetiracetam, which is classified as a Second-Generation Anticonvulsant or Antiepileptic Drug (AED). This substance is a synthetic compound belonging to the unique pyrrolidone class of chemicals and is utilized to stabilize abnormal electrical activity in the brain. The drug's general purpose is the control and reduction of the frequency and severity of various seizures associated with epilepsy. Levetiracetam is specifically designated as an AED for use in treating seizure disorders.


Composition and Available Forms of Levetiracetam-Rex

This product is a single-agent product, containing only the therapeutically active substance, Levetiracetam, combined with the necessary base/vehicle components for formulation. This active ingredient is distinct from older AEDs, which often operate via different neurochemical pathways. Levetiracetam is available for both oral and intravenous (IV) route of administration. The available dosage forms include various tablets (immediate-release and extended-release long-acting versions), an oral solution (liquid, often beneficial for pediatric or elderly populations), and a sterile concentrate for infusion for IV use. The chemical structure of Levetiracetam belongs to the pyrrolidone class, which distinguishes it from other AED classes.


How Does Levetiracetam Stabilize Brain Activity?

The stabilizing effect is achieved because Levetiracetam functions as a Brain Signaling Stabilizer by selectively binding to the Synaptic Vesicle Protein 2A (SV2A) in the central nervous system. This highly targeted molecular action modulates communication between nerve cells, helping to prevent the rapid, uncontrolled nerve firing that propagates seizure activity. This mechanism offers the essential general benefit of acting as a Seizure Activity Modulator, which effectively mitigates the hypersynchronization of electrical disturbances, enabling the patient to achieve better control over brain activity.

Regulatory References

  1. European Public Assessment Report (EPAR) for Levetiracetam
  2. Levetiracetam EPAR - Summary for the public
Advertisements

What side effects are possible with Levetiracetam-Rex?

Possible Side Effects and Safety Information: Levetiracetam-Rex

Safety Profile Summary

Levetiracetam-Rex is associated with a range of adverse effects that affect various system-organ classes, including the Nervous System, Psychiatric, and Infections and Infestations systems. Official regulatory documents categorize side effects by frequency.

Adverse Reaction Categories

  • Very Common (1/10): Nasopharyngitis (cold-like symptoms), somnolence (sleepiness), and headache.
  • Common (1/100 to < 1/10): Fatigue, dizziness, coordination abnormalities, hostility/aggression, depression, irritability, and anorexia.

Serious and Clinically Significant Risks

The medication carries warnings for serious, rare events that require prompt medical attention:

  • Suicidal Behavior and Ideation: Monitoring for new or worsening depression and suicidal thoughts or behavior is officially required.
  • Serious Dermatological Reactions: This includes life-threatening conditions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity. DRESS may present with fever and swollen lymph nodes without a rash and can affect internal organs like the liver and kidneys.
  • Behavioral and Psychotic Symptoms: Significant behavioral abnormalities, including aggression and psychotic symptoms, have been reported and necessitate monitoring. These are noted to be more frequent in the pediatric population.
  • Hematologic Abnormalities: Rare decreases in various blood cell counts have been described.

Population-Specific Safety Considerations

Since the drug is primarily cleared by the kidneys, dose adjustments based on estimated renal function (creatinine clearance) are mandatory for adults with renal impairment, including the elderly population. Gradual withdrawal of the medication is required to minimize the potential for increased seizure frequency.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Levetiracetam-Rex has been formally documented in regulatory sources to present with severe central nervous system (CNS) and respiratory manifestations. The official profile for overexposure is defined by specific signs and mandated management protocols.

Documented Overdose Presentations and Actions

Feature Official Regulatory Documentation
Manifestations Somnolence, agitation, hostility, aggression, and a confusional state are listed clinical manifestations. Severe outcomes requiring urgent care include coma, respiratory depression, and depressed level of consciousness.
Emergency Actions Seek immediate medical attention for these life-threatening symptoms. The official label confirms that no specific antidote is known, meaning treatment must be symptomatic and supportive.
Management Procedures Procedures such as gastric lavage for unabsorbed drug removal or hemodialysis may be indicated. Hemodialysis is documented to remove approximately 50% of the active ingredient from the systemic circulation.

Population-Specific Overdose Note

The regulatory documentation notes a specific risk of accidental, high-magnitude overexposure, reported up to 10-fold, associated with the oral solution in children aged 6 months to 11 years. This population-specific hazard is directly linked to administration errors involving the dosing device.

The regulatory documents define the overdose profile by specifying severe neurological and respiratory compromise as the primary concern. The required help-seeking condition is explicitly tied to the occurrence of these serious, life-threatening events. Management strategies are officially based on supportive care and procedural drug removal methods.

Advertisements

Therapeutic Uses of Levetiracetam-Rex

What Levetiracetam-Rex Treats: Main Uses and Benefits

Levetiracetam-Rex is primarily used for managing seizure manifestations across a wide spectrum of epilepsy, a condition marked by periods of heightened symptoms of increased neurological activity. The core therapeutic domains are relevant for managing specific, distressing manifestations, including the abrupt muscle jerks of myoclonic seizures, the major full-body convulsions of Primary Generalized Tonic-Clonic Seizures, and focal (partial-onset) seizures. The medication is commonly used across extensive patient demographics, including adults, adolescents, children, and infants.

This therapy supports the management of conditions characterized by periods of heightened symptoms, generally applying to both long-term maintenance of chronic epilepsy and situations that involve acute or unstable symptom patterns. This broad use assists with maintaining functional stability and improving day-to-day comfort by easing the impact of symptoms on routine activities across all stages of life.

“This therapy is commonly used to provide support that helps ease the overall symptom burden associated with recurrent seizure activity.”


Quick Fact: Relief for Seizure Manifestations
Symptom focus Convulsive and motor events (myoclonic jerks, tonic-clonic episodes) and focal seizures.
Contextual role Relevant for both short-term symptom stabilization and chronic maintenance therapy across all use-relevant age groups.
Main benefit Contributes to easing the symptom load and assists with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Levetiracetam-Rex — Official Regulatory Information

The eligibility for using Levetiracetam-Rex is defined by a regulatory profile that specifies absolute exclusions and conditional restrictions based on age, organ function, and physiological status.

Contraindicated Populations

This medicine is contraindicated and must not be used by patients with a known hypersensitivity (allergy) to the active substance Levetiracetam or any pyrrolidone derivatives.


Age-Related Eligibility and Restrictions

Population Group Eligibility Status
Adults and Adolescents (16+ years) Standard use for monotherapy and adjunctive therapy.
Children (1 month to <16 years) Eligible for adjunctive therapy, with a minimum age threshold of 1 month of age.
Infants under 1 month Use is not established; safety and efficacy are not defined.
Older Adults (65+ years) Standard use, but requires renal function assessment for appropriate dose selection.

Condition-Based and Physiological Restrictions

Eligibility is conditional for individuals with impaired renal function (kidney impairment) and those with severe hepatic impairment (liver impairment), as the medicine is cleared by the kidneys and requires an assessment of renal status. Use during pregnancy and lactation is also conditional; the label states use is only permitted if the potential benefit outweighs the potential risk. Furthermore, patients with a history of psychiatric conditions or those who exhibit suicidal ideation are eligible but require close, mandated monitoring.

Advertisements

What should I know about interactions with other medicines?

Official Interaction Profile for Levetiracetam-Rex

The documented interaction profile for Levetiracetam-Rex is characterized by a low potential for metabolic drug-drug interactions due to its unique clearance pathway. The only formal contraindication in this context is known hypersensitivity to the product.

Pharmacokinetic Interaction Patterns

Interaction Target Official Regulatory Statement
Metabolic Enzymes (CYP450) The drug is not extensively metabolized by, nor does it inhibit or induce, major liver cytochrome P450 isoforms. This profile minimizes the risk of many common metabolic interactions.
Enzyme-Inducing AEDs Co-administration with enzyme-inducing Antiepileptic Drugs (AEDs), such as carbamazepine, results in an approximate 22% increase in the apparent clearance of Levetiracetam.
Co-Medication Levels Levetiracetam does not significantly affect the plasma concentrations of many co-administered substances, including valproic acid, lamotrigine, digoxin, warfarin, or oral contraceptives.
Food & Timing The bioavailability of the medicine is officially documented as not affected by food. Regulatory information does not specify mandatory timing separation requirements.

Clearance and Population-Specific Note

The apparent body clearance of Levetiracetam is directly correlated with creatinine clearance. This relationship establishes that the drug's exposure is altered by the physiological condition of renal impairment. The official profile requires recognition of this altered clearance, which is essential for defining the drug's overall interaction structure.

Advertisements

Mechanism of Action

Modulation of the Synaptic Vesicle Protein (SV2A)

Levetiracetam's mechanism centers on a unique, high-affinity interaction with the Synaptic Vesicle Protein 2A (SV2A), which is essential for regulating neurotransmitter release at the presynaptic nerve terminal. This binding acts as a key modulator of the synaptic vesicle cycle, influencing the efficiency of communication between brain cells and contributes to the attenuation of uncontrolled neuronal excitability.


Stabilizing Excitatory Signal Propagation

The action on SV2A alters the process of Ca^2+-dependent neurotransmitter release, modulating the excessive output of excitatory signals, particularly during periods of high-frequency firing. This cellular stabilization limits the widespread neuronal hypersynchronization by constraining the ability of overactive neurons to propagate their pathological electrical discharge across surrounding networks. The mechanism is associated with the establishment of a state of attenuated electrical discharge within the CNS.

Advertisements

Dosage and Administration Information

Levetiracetam-Rex is used based on specific administration and dosing protocols. The medicine is primarily taken orally using immediate-release (IR) tablets, extended-release (ER) tablets, or an oral solution. A sterile intravenous (IV) concentrate is indicated for temporary use when the oral route is not feasible, with a direct dose-for-dose equivalent used for conversion between routes.

Official Dosing and Administration

Adult Dosing: The standard practice for immediate-release forms involves initiating a dose of 500 mg taken twice daily, which is then gradually increased by 500 mg twice daily approximately every two weeks. This titration continues up to a maximum recommended daily dose of 3000 mg. Extended-release tablets, conversely, follow a once-daily schedule. The medication may be taken with or without food.

Special Conditions: Clinical protocols involve a reduction in the total daily dose for patients with impaired kidney function, as defined by their creatinine clearance. Pediatric dosing (for patients under 50 kg) is determined on a weight-based basis (mg/kg), reflecting necessary adjustments for this population. When administering the IV form, the concentrate must be diluted and infused over a controlled period of 15 minutes. Furthermore, extended-release tablets must be swallowed whole and should not be crushed or chewed. When the medication is to be discontinued, the dosage must be gradually reduced (tapered) over time.

Advertisements

Recent Clinical Evidence

Evidence for Use in Focal Onset Seizures

Research for Levetiracetam-Rex (levetiracetam) in people with focal onset seizures relies primarily on short-term, randomized, placebo-controlled trials. These studies are considered the gold standard for clinical research and were primarily conducted with the medicine used as an add-on to existing seizure treatments. Researchers monitored seizure frequency in adults, adolescents, and children as young as one month of age to assess patterns of change in the observed populations.

Evidence for Use in Generalized Seizures

The medicine was also evaluated in key randomized trials for its use as an add-on therapy for Primary Generalized Tonic-Clonic Seizures (PGTCS) in patients aged six years and older. Another controlled trial explored its use for Myoclonic Seizures, focusing on adolescents and adults with Juvenile Myoclonic Epilepsy (JME). The studies found that findings describe patterns observed related to changes in seizure frequency during the controlled study periods.

Long-Term Studies and Research Gaps

For a view of use over extended periods, research relies on open-label extension studies that follow participants for longer durations after the initial controlled trials end. While these provide context, the evidence quality varies compared to the initial randomized trials due to the lack of a placebo comparison. Overall, there is limited information for long-term outcomes and the durability of the effect after several years of use.

Data for certain groups remain limited. Comparative evidence, such as head-to-head randomized trials directly comparing Levetiracetam-Rex against a wide range of newer seizure medicines, is not extensive, meaning comparative evidence is lacking in some areas. Research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Key Studies & References

  1. Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Levetiracetam-Rex (FAQ)


Q: How is Levetiracetam-Rex different from regular Levetiracetam?

A: The 'Rex' name typically refers to an extended-release (ER) formulation of the medicine. Official labeling indicates that immediate-release Levetiracetam is usually taken twice daily, while the ER version is taken once daily, according to official administration instructions.

Q: Is Levetiracetam-Rex mainly for epilepsy or are there other common uses?

A: Levetiracetam is officially approved for the treatment of seizures associated with epilepsy. Any use for conditions other than those listed in the official indications is considered off-label and is not covered by regulatory approvals.

Q: Is it normal to feel a bit 'foggy' or have trouble concentrating on Levetiracetam-Rex?

A: Official information notes that the medication can cause Central Nervous System (CNS) adverse reactions such as dizziness, sleepiness, and confusion. These CNS effects may be experienced as a feeling of being 'foggy' or having difficulty with concentration.

Q: Does Levetiracetam-Rex interact with common pain relievers like ibuprofen?

A: Regulatory documents indicate that Levetiracetam has a low potential for metabolic drug-drug interactions because it is not significantly processed by major liver enzymes. Specific interactions with common over-the-counter pain relievers like ibuprofen are not explicitly listed in the official documents.

Q: Can people taking Levetiracetam-Rex still drive or operate heavy machinery?

A: Official warnings advise against driving or operating complex machinery until an individual is certain how the medicine affects their ability to perform these tasks, due to common side effects like somnolence (sleepiness) and fatigue.

Q: What are the long-term effects of being on Levetiracetam-Rex for many years?

A: The drug’s initial effectiveness is established through short-term, controlled clinical trials. Official documents state that information on the long-term effects and safety profile over many years of continuous use is limited and mostly comes from less rigorous follow-up studies.

Q: Is Levetiracetam-Rex considered a controlled substance?

A: According to official government classifications, Levetiracetam is not scheduled as a controlled substance in the United States or under comparable international drug scheduling laws.

Q: Will Levetiracetam-Rex still work if I take antacids or stomach medicines?

A: The official clinical data suggests that the absorption and clearance of Levetiracetam are not significantly altered by co-administered drugs that affect kidney transport. This profile suggests a low risk of interaction with common stomach medicines.

Q: Can taking Levetiracetam-Rex cause changes in weight?

A: Regulatory documents list anorexia (loss of appetite) as a common side effect of Levetiracetam. While the drug is often considered weight-neutral, post-marketing reports have indicated that weight changes can occur.

Q: How long does Levetiracetam-Rex stay in your system after you stop taking it?

A: According to official pharmacology data, the average time for the concentration of Levetiracetam to be halved in the body (the half-life) is about 7 hours in adults. The half-life may be longer for older individuals.

Q: Is there any research on Levetiracetam-Rex's use in migraine prevention?

A: Official regulatory documents do not list migraine prevention as an approved use for this medicine. However, use for the prevention of migraines has been investigated in clinical studies, but is not included in the official regulatory indications.

Q: Are there common blood tests required when you are taking Levetiracetam-Rex?

A: Official labeling notes that rare decreases in blood cell counts have been described, which may require monitoring. Routine therapeutic drug monitoring (TDM) is generally not required, but blood tests may be required to monitor kidney function, as the drug is cleared primarily by the kidneys.

Q: Does Levetiracetam-Rex cause dependency or withdrawal symptoms if stopped suddenly?

A: Official warnings advise against abrupt discontinuation, as it may lead to an increase in seizure frequency or status epilepticus. When stopping the medicine, the dosage must be gradually reduced over time.

Q: Does Levetiracetam-Rex cause hair loss?

A: Official post-marketing experience reports have included observations of hair loss or thinning of the hair. These reports indicate it is a possible side effect, though it was not frequently observed in the initial controlled clinical trials.

Q: Can Levetiracetam-Rex affect liver function over time?

A: The official product information notes that the medicine requires careful assessment in patients with severe hepatic (liver) impairment. Furthermore, a rare but serious adverse reaction, DRESS/Multiorgan Hypersensitivity, can potentially involve effects on internal organs, including the liver.

Q: Do side effects from Levetiracetam-Rex usually go away after the first few weeks?

A: Many of the common, milder side effects, such as sleepiness and dizziness, tend to appear early in treatment. The dosage is often gradually adjusted upward, which may allow the body time to adjust and potentially minimize these initial side effects.

Q: Does taking Levetiracetam-Rex require you to change your diet in any significant way?

A: According to official pharmacological studies, the absorption of Levetiracetam is not affected by food, meaning it can be taken with or without meals. No significant dietary changes are strictly mandated by regulatory authorities.

Q: Is Levetiracetam-Rex safe for adolescents?

A: Yes, Levetiracetam is approved for use as adjunctive therapy in children and adolescents. However, official warnings note that behavioral abnormalities (like aggression and irritability) are reported as occurring more frequently in the pediatric population (4–16 years) compared to adults.

Q: Are there any known interactions between Levetiracetam-Rex and herbal supplements like St. John's Wort?

A: Official regulatory texts do not specifically list St. John's Wort. However, the official label suggests that any co-administration should be monitored, as Central Nervous System (CNS) effects, such as increased drowsiness, may be additive.

Q: Does Levetiracetam-Rex lose its effectiveness over time (tolerance build-up)?

A: Official clinical evidence acknowledges that the durability of the effect over extended periods is an area where detailed research is limited. Regulatory information does not specifically state that tolerance (loss of effectiveness) is a common pattern for this medicine.

Q: Can Levetiracetam-Rex cause allergic reactions?

A: Yes, Levetiracetam is contraindicated (must not be used) if a patient has a known hypersensitivity or allergy to the active substance. Rare, severe allergic reactions, including conditions like anaphylaxis, have been reported in official documents.

Q: Are generic versions of Levetiracetam-Rex just as effective as the brand name?

A: In the United States, generic versions are approved by the FDA after manufacturers demonstrate they are bioequivalent to the brand-name drug. Bioequivalence means the generic is absorbed and delivered to the bloodstream at the same rate and extent as the reference drug.

Q: How is Levetiracetam-Rex eliminated from the body?

A: The body primarily eliminates Levetiracetam via the urine. Most of the drug is excreted as the unchanged drug through glomerular filtration by the kidneys, which is why kidney function is a key consideration for dosing.

Q: How common is it for patients to experience dizziness on Levetiracetam-Rex?

A: In controlled adult clinical trials, dizziness was reported as a common adverse reaction. One trial reported it in 1% of Levetiracetam-treated patients versus 0% of placebo-treated patients, placing it among the most common CNS-related side effects.

Q: What is the benefit of using Levetiracetam-Rex over similar seizure drugs?

A: Official evidence highlights the drug's effectiveness against placebo for various seizure types. However, regulatory documents note that direct, randomized head-to-head trials against many newer seizure medicines are not extensive, which limits definitive comparisons of superiority.

Q: Does Levetiracetam-Rex have different side effects in children compared to adults?

A: Yes. Official clinical trial data indicates that behavioral abnormalities such as aggression and irritability are reported as occurring more frequently in the pediatric population (4–16 years) compared to adults.

Q: Is there a maximum time a person should take Levetiracetam-Rex?

A: Official regulatory labeling does not set a specific maximum duration for how long the medication can be taken orally. It is generally used for as long as needed to control seizures.

Advertisements

How should Levetiracetam-Rex be stored and disposed of?

The official requirements for Levetiracetam storage and disposal are defined by regulatory authorities to ensure product stability and safety.

Storage Conditions

The medicine, including tablets and oral solution, must be stored at Controlled Room Temperature (CRT).

Scope Item Official Regulatory Requirement
Storage Temperature 20 C to 25 C (68 F to 77 F). Excursions between 15 C and 30 C are permitted.
Handling Tablets must be kept in the original container to maintain integrity.
Child Safety Keep the medicine out of the sight and reach of children at all times.

Disposal Instructions

Disposal must adhere to specific instructions to prevent environmental contamination:

  • Dispose of any unused or expired product according to local requirements for medicinal products.
  • It must not be discarded via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levetiracetam-Rex found in:

A-Z Index: